Prognostic Molecular Markers in Patients With Myelodysplastic Syndrome

Samsung Medical Center

Status: Completed

Conditions: Myelodysplastic Syndrome

Treatments: Genetic: spliceosome

Study type: Observational

Funder types: Other

Identifiers

NCT02060409

2012-01-081-003

Details and patient eligibility

About

In the era of hypomethylating agent in MDS treatment, the investigators aimed to investigate the prognostic impact of mutations in spliceosome machinery genes (SRSF2, U2AF1, and ZRSR2) on the outcomes of 1st line decitabine treatment in MDS.

Full description

A number of studies have tried to investigate clinical impact of mutations in spliceosomal machinery genes in MDS but they failed to demonstrate a consistent prognostic relevance. Moreover, the clinical impact of these mutations on the outcomes of hypomethylating agent treatment in MDS has never been explored yet. The investigators investigated the prognostic impact of mutations in spliceosome machinery genes (SRSF2, U2AF1, and ZRSR2) on the outcomes of 1st line decitabine treatment in MDS.

Enrollment: 58 patients

Sex: All

Ages: 17 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• de novo MDS patients were included in the study who had received 1st line decitabine treatment and had adequate genomic DNA from pretreated bone marrow samples

Exclusion criteria

• therapy-related MDS

Trial design

58 participants in 1 patient group

spliceosome

Description:

patient who have available data for spliceosome mutation status

Treatment:

Genetic: spliceosome